MCID: PPT005
MIFTS: 58

Peptic Ulcer Disease

Categories: Gastrointestinal diseases

Aliases & Classifications for Peptic Ulcer Disease

MalaCards integrated aliases for Peptic Ulcer Disease:

Name: Peptic Ulcer Disease 12 15
Peptic Ulcer 36 29 54 42 43 71
Acute Peptic Ulcer Without Hemorrhage and Without Perforation 12
Acute Peptic Ulcer with Hemorrhage and Perforation 12
Acute Peptic Ulcer with Hemorrhage 12

Classifications:



External Ids:

Disease Ontology 12 DOID:750
KEGG 36 H01634
ICD9CM 34 533
MeSH 43 D010437
NCIt 49 C3318
SNOMED-CT 67 13200003
ICD10 32 K27
UMLS 71 C0030920

Summaries for Peptic Ulcer Disease

MedlinePlus : 42 A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse. To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Peptic Ulcer Disease, also known as peptic ulcer, is related to active peptic ulcer disease and stomach disease, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Peptic Ulcer Disease is S100A8 (S100 Calcium Binding Protein A8), and among its related pathways/superpathways are PEDF Induced Signaling and Cytokine Signaling in Immune system. The drugs Acetylcysteine and Enalaprilat have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and small intestine, and related phenotypes are digestive/alimentary and homeostasis/metabolism

KEGG : 36 Peptic ulcer is a common disorder of gastrointestinal system characterized by mucosal damage secondary to pepsin and gastric acid secretion. It usually occurs in the stomach and proximal duodenum. Typical symptoms include episodic burning epigastric pain, loss of appetite, and weight loss. Pain usually occurs two to five hours after meals or on an empty stomach. The most common causes of peptic ulcer are Helicobacter pylori infection and use of nonsteroidal anti-inflammatory drugs (NSAIDs). Smoking increases the risk of ulcer recurrence and slows healing. Most patients are treated successfully with eradication of H. pylori and/or avoidance of NSAIDs, along with the appropriate use of antisecretory therapy. About 25 percent of patients with peptic ulcer have a serious complication such as hemorrhage, perforation, or gastric outlet obstruction. Administration of proton pump inhibitors (PPIs) and endoscopic therapy control most bleeds.

Wikipedia : 74 Peptic ulcer disease (PUD) is a break in the inner lining of the stomach, the first part of the small... more...

Related Diseases for Peptic Ulcer Disease

Diseases related to Peptic Ulcer Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 772)
# Related Disease Score Top Affiliating Genes
1 active peptic ulcer disease 34.4 PTGS2 PTGS1 HRH2 CYP2C19 ATP4A
2 stomach disease 32.9 PTGS2 PTGS1 HRH2 GHRL
3 zollinger-ellison syndrome 32.9 SCT MEN1 HRH2 GRP GAST ATP4A
4 gastrointestinal ulceration, recurrent, with dysfunctional platelets 32.5 S100A8 PTGS2 PTGS1 HRH2 GAST
5 multiple endocrine neoplasia, type i 32.4 SCT MEN1 GHRL GAST ATP4A
6 helicobacter pylori infection 32.2 S100A8 IL1B GAST CYP2C19 CXCL8
7 peptic ulcer perforation 31.9 S100A8 HRH2 GAST ATP4A
8 duodenitis 31.9 S100A8 GAST ATP4A
9 gastroduodenitis 31.4 S100A8 GAST ATP4A
10 opisthorchiasis 31.3 TNF IL1B CXCL8
11 bile reflux 31.3 S100A8 PTGS2 GAST ATP4A
12 gastric ulcer 31.2 TNF S100A8 PTGS2 PTGS1 IL1RN IL1B
13 dumping syndrome 31.2 SCT GHRL GAST
14 duodenogastric reflux 31.1 SCT GAST ATP4A
15 irritable bowel syndrome 31.1 TNF IL10 GHRL CXCL8
16 microinvasive gastric cancer 31.1 TP53 S100A8 GAST ATP4A
17 peritonitis 31.0 TNF IL1B IL10 CXCL8
18 gastric lymphoma 31.0 TP53 S100A8 ATP4A
19 bronchitis 30.9 TNF IL1B IL10 CXCL8 CAT
20 islet cell tumor 30.9 SCT MEN1 GAST
21 cholecystitis 30.9 TP53 S100A8 CAT
22 hernia, hiatus 30.9 HRH2 GAST CYP2C19 ATP4A
23 duodenal ulcer 30.9 TNF SCT S100A8 IL1RN IL1B IL10
24 diarrhea 30.9 TNF SCT IL1B IL10 GAST CXCL8
25 ileus 30.9 TNF IL1B IL10 GHRL
26 allergic hypersensitivity disease 30.8 TNF IL10 HRH2 CXCL8
27 end stage renal failure 30.8 TNF PTGS2 IL1RN GAST CAT
28 candidiasis 30.8 TNF IL1B IL10 CXCL8
29 gastrinoma 30.8 SCT MEN1 GRP GAST
30 acute cystitis 30.8 TNF IL10 CXCL8
31 obstructive jaundice 30.7 TNF GRP CXCL8
32 peptic esophagitis 30.7 S100A8 PTGS2 IL1B HRH2 GAST CYP2C19
33 gastritis, familial giant hypertrophic 30.7 MEN1 GAST ATP4A
34 rosacea 30.7 TNF S100A8 CXCL8
35 esophagitis 30.7 TP53 TNF PTGS2 IL1B IL10 HRH2
36 cytomegalovirus infection 30.7 TNF IL1B CXCL8
37 salmonellosis 30.7 TNF IL1B IL10
38 lung disease 30.7 TP53 TNF S100A8 IL1B IL10 GRP
39 crohn's disease 30.6 TNF S100A8 IL1B IL10 CXCL8
40 pancreatitis 30.6 TP53 TNF SCT HRAS
41 pyoderma 30.6 TNF IL1RN CXCL8
42 pyoderma gangrenosum 30.6 TNF IL1RN CXCL8
43 scrub typhus 30.6 TNF IL1B IL10
44 ulcerative colitis 30.6 TNF IL1RN IL1B IL10 CXCL8
45 pleurisy 30.6 TNF IL1RN CXCL8
46 neurofibromatosis, type iv, of riccardi 30.6 TP53 MEN1 HRAS
47 migraine with or without aura 1 30.6 TNF PTGS2 IL1B ATP4A
48 alcoholic hepatitis 30.5 TNF IL1B IL10 CXCL8
49 gastric cancer 30.5 TP53 S100A8 PTGS2 IL1RN IL1B HRH2
50 fibromyalgia 30.5 TNF IL1B IL10 CXCL8

Comorbidity relations with Peptic Ulcer Disease via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Peptic Ulcer Disease:



Diseases related to Peptic Ulcer Disease

Symptoms & Phenotypes for Peptic Ulcer Disease

UMLS symptoms related to Peptic Ulcer Disease:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, signs and symptoms, digestive, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Peptic Ulcer Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.06 ATP4A GAST GHRL HRAS HRH2 IL10
2 homeostasis/metabolism MP:0005376 10.03 ATP4A CAT GAST GHRL HRAS HRH2
3 endocrine/exocrine gland MP:0005379 10 ATP4A GAST GHRL HRAS HRH2 IL10
4 immune system MP:0005387 9.7 ATP4A GAST IL10 IL1B IL1RN MEN1
5 neoplasm MP:0002006 9.4 ATP4A CAT GAST HRAS IL10 IL1B

Drugs & Therapeutics for Peptic Ulcer Disease

Drugs for Peptic Ulcer Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 329)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
2
Enalaprilat Approved Phase 4 76420-72-9 6917719
3
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
4
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
5
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
6
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
7
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
8
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
9
Coal tar Approved Phase 4 8007-45-2
10
Ibuprofen Approved Phase 4 15687-27-1 3672
11
Atorvastatin Approved Phase 4 134523-00-5 60823
12
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
13
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
14
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
15
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
16
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
17
Azithromycin Approved Phase 4 83905-01-5 55185 447043
18
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560 441411
19
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
20 Orange Approved Phase 4
21
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
22
Ticagrelor Approved Phase 4 274693-27-5 9871419
23
Bisoprolol Approved Phase 4 66722-44-9 2405
24
Dalteparin Approved Phase 4 9005-49-6
25 Bemiparin Approved, Investigational Phase 4 91449-79-5
26
Phylloquinone Approved, Investigational Phase 4 84-80-0
27
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
28
Thrombin Approved, Investigational Phase 4
29
Potassium citrate Approved, Investigational, Vet_approved Phase 4
30
Misoprostol Approved Phase 4 59122-46-2 5282381
31
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
32
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
33
Clarithromycin Approved Phase 4 81103-11-9 84029
34
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
35
Ofloxacin Approved Phase 4 82419-36-1 4583
36
Nimodipine Approved, Investigational Phase 4 66085-59-4 4497
37
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
38
Famotidine Approved Phase 4 76824-35-6 3325
39
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
40
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
41 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
42
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
43
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
44
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
45
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
46
Mycophenolic acid Approved Phase 4 24280-93-1 446541
47
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 4 303-98-0 5281915
48
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
49
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
50
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054

Interventional clinical trials:

(show top 50) (show all 339)
# Name Status NCT ID Phase Drugs
1 Comparison of the Efficacy of Sequential Therapy and Bismuth Quadruple Therapy in the First Line and Second Line Therapy for Helicobacter Pylori Infection- A Multi-center Randomized Trial Unknown status NCT03156855 Phase 4 14-day sequential therapy;Bismuth quadruple therapy
2 Esomeprazole or Famotidine in the Management of Aspirin Related Non-ulcer Dyspepsia - a Double Blind Randomized Control Study Unknown status NCT00978159 Phase 4 esomeprazole;Famotidine
3 Phase IV Study Comparing Helicobacter Pylori Empiric Eradication With Test-Guided Treatment in Patients With Peptic Ulcer Bleeding Unknown status NCT00687336 Phase 4
4 Phase 4, Prospective, Randomized Study Comparing 14-day Non-bismuth Quadruple "Hybrid" and "Concomitant" Therapies for Helicobacter Pylori Eradication in Settings With High Clarithromycin Resistance Unknown status NCT01464060 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
5 Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia: a Multi-national, Randomised, Double-blind, Placebo-controlled Study Unknown status NCT02134405 Phase 4 Rebamipide;Placebo (for Esomeprazole);Esomeprazole
6 Prospective, Randomized Trial of Hemospray Plus Epinephrine Injection Versus Endoscopic Hemoclip Plus Epinephrine Injection in Nonvariceal Upper Gastrointestinal Bleeding Unknown status NCT02537353 Phase 4 Hemospray;Adrenaline
7 Oral vs Intravenous Proton Pump Inhibitor(PPI) in Patients With Peptic Ulcer Bleeding After Successful Endoscopic Therapy- a Prospective Randomized Comparative Trial Unknown status NCT01123031 Phase 4 lansoprazole;esomeprazole
8 Compare Gastric Acid Suppression of Esomeprazole by Oral or Intravenous Administration - A Randomized Trial Unknown status NCT00471029 Phase 4 esomeprazole
9 A Double Blind Study Comparing Low Dose and High Dose IV Esomeprazole After Successful Endoscopic Therapy in Patients With Peptic Ulcer Bleeding Unknown status NCT01275937 Phase 4 Esomeprazole;esomeprazole
10 Aspirin and the Antiproteinuric Effect of Enalapril in Microalbuminuric Type 2 Diabetes Mellitus Patients: a Randomized, Double-Blind, Placebo-Controlled Study Unknown status NCT00427271 Phase 4 aspirin
11 Comparison of Triple Therapy Regimens Effectiveness Over 10 Days and 14 Days in Eradication of Helicobacter Pylori Infection: Double Blind Randomized Clinical Trial Unknown status NCT03134378 Phase 4 Rabeprazole Sodium 20mg;Clarithromycin 500mg;Amoxicillin 500 Mg
12 "Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors" Unknown status NCT02028234 Phase 4 Pantoprazole,;Omeprazole
13 Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
14 Comparison of the Efficacy of Triple Therapy With or Without Acetylcysteine in the First Line of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial Unknown status NCT02249546 Phase 4 N-acetylcysteine + PPI-amoxicillin-clarithromycin;PPI-amoxicillin-clarithromycin
15 Optimal Anti-Platelet Treatment for Patients With Stent IMplantation And Clopidogrel Low Response: OPTIMAL Study Unknown status NCT01955200 Phase 4 Ticagrelor;Clopidogrel;Cilostazol;Clopidogrel;Clopidogrel
16 A Clinical Study of the Efficacy of Esomeprazole or Rabeprazole on the Pattern of Release of Pro- and Anti-inflammatory Cytokines From Gastric Mucosa of Patients With Peptic Ulcer Disease Completed NCT00534443 Phase 4
17 Comparison of Conventional Triple Therapy Versus Sequential Therapy for H. Pylori in Peptic Ulcer Disease: Prospective Randomized Trial Completed NCT01418300 Phase 4 sequential versus triple
18 Prevention of Recurrent Idiopathic Gastroduodenal Ulcer Bleeding: a Double-blind Randomized Trial Completed NCT01180179 Phase 4 Lansoprazole;Famotidine
19 Intraluminal Therapy for Helicobacter Pylori Infection Completed NCT03124420 Phase 4 Lansoprazole;Amoxicillin;Clarithromycin
20 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03524833 Phase 4 Metronidazole;Lansoprazole, Amoxicillin, Metronidazole
21 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03521726 Phase 4 Amoxicillin;Rabeprazole, Amoxicillin
22 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03516669 Phase 4 Clarithromycin;Amoxicillin, Clarithromycin
23 A Randomized Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection Completed NCT01219764 Phase 4 Rabeprazole, metronidazole, Clarithromycin, Amoxicillin
24 Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection Completed NCT02541786 Phase 4 dexlansoprazole based triple therapy;rabeprazole-based triple therapy
25 Prospective, Randomized Controlled Trial Comparing Amoxicillin and Metronidazole Based Bismuth-containing Quadruple Therapy With Amoxicillin and Clarithromycin Based Quadruple Therapy for First-line Helicobacter Pylori Eradication Completed NCT02175901 Phase 4 Lansoprazole;Bismuth Potassium Citrate;Amoxicillin;Metronidazole;Clarithromycin
26 Proton Pump Inhibitor Treatment Stop: Discontinuation of Acid-suppressive Medication Among Long-term Users in a Primary Health Care Setting Completed NCT00120315 Phase 4 esomeprazole
27 Possible Drug Interaction Between Clopidogrel and Ranitidin or Omeprazole in Patients With Stable Coronary Heart Disease: a Comparative Study Completed NCT01896557 Phase 4 omeprazole;Ranitidine;Clopidogrel
28 Relation of Metabolic Rate of Omeprazole and Eradication of Helicobacter Pylori Infection - A Combination of Clinical and Pharmacogenetic Study Completed NCT00854451 Phase 4 omeprazole plus amoxicillin;omeprazole plus amoxicillin;omeprazole plus amoxicillin;omeprazole plus amoxicillin
29 Sequential Versus Concomitant Therapy for Helicobacter Pylori Infection Completed NCT00656968 Phase 4 10-day sequential treatment;10-day concomitant therapy
30 Sequential Helicobacter Pylori Eradication Therapy in Myanmar; a Randomized Clinical Trial of Efficacy and Tolerability Completed NCT04132479 Phase 4 Clarithromycin 500mg;Amoxicillin 500mg;Tinidazole 500mg;Rabeprazole 20mg;Clarithromycin 500mg;Amoxicillin 500mg;Tinidazole 500mg;Rabeprazole 20mg
31 Phase 4 Study of Intravenous Proton Pump Inhibitor in Patients With Peptic Ulcer Bleeding After Successful Endoscopic Therapy- a Prospective Randomized Comparative Trial Completed NCT00731601 Phase 4 pantoprazole;pantoprazole
32 The Influence of CYP2C19 Genetic Polymorphism and Dosage of Rabeprazole on the Accuracy of Proton-Pump Inhibitor Testing in Chinese Patients With Gastroesophageal Reflux Disease Completed NCT00354757 Phase 4 rabeprazole
33 The Dissemination of Consensus Recommendations on the Management of Canadian Patients With Non Variceal Upper Gastrointestinal Bleeding: A National Cluster Randomized Trial of a Multifaceted Tailored Implementation Strategy Completed NCT00840008 Phase 4
34 A Prospective Randomized Double-Blind Trial Comparing 3 Doses of Oral Ibuprofen in Management of Mild to Moderate Pain in Adult Patients in the ED Completed NCT03441269 Phase 4 Oral Ibuprofen
35 Comparison of Twq Different Regimen of Vaginal Misoprostol for Nid Trimester MTP Completed NCT00401440 Phase 4 Misoprostol;Misoprostol
36 A Greek, Single Center, Randomized, Double Blind Controlled Clinical Study Comparing the 10-day Versus the 14-day Concomitant Proton Pump Inhibitor [PPI] + Amoxicillin + Metronidazole + Clarithromycin (PAMC) Therapeutic Scheme as First-line Treatment Strategy for the Eradication of H. Pylori Infection Completed NCT02959255 Phase 4 Esomeprazole
37 The Therapeutic Role of Albumin Supply on Peptic Ulcer Bleeding and the Correlation Between Clinical Course and Expression of Serum Response Factor on Ulcer Tissue and Superoxide Free Radical in Blood Completed NCT01822600 Phase 4 Human albumin;Omeprazole
38 Famotidine vs. Pantoprazole to Prevent Recurrent Aspirin-Induced Peptic Ulcer/Erosion - a Randomized Controlled Study Completed NCT00843063 Phase 4 pantoprazole vs famotidine
39 A Comparison of Two Therapeutic Strategies for the Treatment of Aspirin-associated Peptic Ulcers Completed NCT01353144 Phase 4 aspirin
40 The Feasibility of Fast-track Surgery for Perforated Peptic Ulcers. A Prospective Randomized Clinical Trial Completed NCT01620671 Phase 4
41 A Randomized Controlled Trial of Triple Therapy Versus Sequential Therapy Versus Concomitant Therapy as First Line Treatment for Helicobacter Pylori Infection Completed NCT02092506 Phase 4 10 day triple therapy;10 day sequential therapy;10 day concomitant therapy
42 Comparison of Efficiency of High Dose Atorvastatin and Endothelial Progenitor-Capture Stents and Bare Metal Stents in Reduction of Neointimal Formation in Patients With Non ST-Segment Elevation Acute Coronary Syndromes Completed NCT00494247 Phase 4
43 The Pilot Study on Tailored Eradication Therapy According to Clarithromycin Resistance in Helicobacter Pylori Patients Completed NCT02648659 Phase 4 Ilaprazole;Amoxicillin;Clarithromycin;Metronidazole
44 Eradication of Helicobacter Pylori According to 23S rRNA Point Mutations Associated With Clarithromycin Resistance Completed NCT01453036 Phase 4
45 Administration of Intravenous Proton Pump Inhibitor Prior to Endoscopy [APPE] in Patients With Upper Gastrointestinal Bleeding; a Double-Blind Placebo-Controlled Randomised Study. Completed NCT00164866 Phase 4 Omeprazole
46 Helicobacter Pylori Treatment Completed NCT01668927 Phase 4 Proton Pump Inhibitor;Bismuth;Metronidazole;Tetracycline;Furazolidone;Amoxicillin
47 Effects of 2 Different Doses of Pantoprazole on Gastric pH and Recurrent Bleeding in Patients Who Bled From Peptic Ulcers Completed NCT00279123 Phase 4 pantoprazole infusion;pantoprazole bolus;no treatment
48 The Studies of the Pathophysiologic Mechanisms of Poor Ulcer Healing & Clinical Improvement to the High Ulcer Rebleeding Rate for Patients With Comorbid Illnesses Completed NCT01591083 Phase 4 esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden)
49 Comparison of Azithromycin or Clarithromycin in 3drugs Protocol of H-pylori Eradication Regimen Completed NCT01667692 Phase 4 azithromycin;clarithmycin
50 Comparison of High Dose Infusion and Low Dose Bolus Intravenous Omeprazole for Treatment of Bleeding Ulcer With Adherent Clot Completed NCT02536989 Phase 4 omeprazole;omeprazole

Search NIH Clinical Center for Peptic Ulcer Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


clidinium
Clidinium bromide
Glycine
Glycopyrrolate
Hyoscyamine
Hyoscyamine hydrobromide
Hyoscyamine Sulfate
Methscopolamine
methscopolamine bromide
methscopolamine nitrate
Propantheline
Propantheline Bromide

Cochrane evidence based reviews: peptic ulcer

Genetic Tests for Peptic Ulcer Disease

Genetic tests related to Peptic Ulcer Disease:

# Genetic test Affiliating Genes
1 Peptic Ulcer 29

Anatomical Context for Peptic Ulcer Disease

MalaCards organs/tissues related to Peptic Ulcer Disease:

40
Testes, Liver, Small Intestine, Pancreas, Colon, Kidney, Heart

Publications for Peptic Ulcer Disease

Articles related to Peptic Ulcer Disease:

(show top 50) (show all 21611)
# Title Authors PMID Year
1
Peptic ulcer disease. 61 42
31578179 2019
2
Efficacy and safety of Hou Gu Mi Xi for peptic ulcer diseases: Study protocol for a randomized controlled trial. 61 42
31335741 2019
3
Reflux esophagitis, functional and non-functional. 42
31594653 2019
4
In situ expression of cagA and risk of gastroduodenal disease in Helicobacter pylori-infected children. 54 61
20038850 2010
5
DNA sequence analysis of cagA 3' motifs of Helicobacter pylori strains from patients with peptic ulcer diseases. 54 61
19850704 2010
6
[Results of evaluating the functional state of the gastric mucosa in duodenal peptic ulcer by means of a test gastropanel in workers engaged in the manufacture of nitrogen compounds]. 54 61
20387669 2010
7
Diverse characteristics of the CagA gene of Helicobacter pylori strains collected from patients from southern vietnam with gastric cancer and peptic ulcer. 54 61
19846630 2009
8
[Guidelines of prevention and treatment for NSAID-related peptic ulcers]. 54 61
19934612 2009
9
Distribution of Helicobacter pylori virulence markers in patients with gastroduodenal diseases in Pakistan. 54 61
19930551 2009
10
Disease association with two Helicobacter pylori duplicate outer membrane protein genes, homB and homA. 54 61
19545429 2009
11
Detection and evaluation of antibodies against neutrophil-activating protein of Helicobacter pylori in patients with gastric cancer. 54 61
19452583 2009
12
[Therapeutic and preventive effects of sulfate-chloride-sodium mineral water in experimental peptic ulcer]. 54 61
19639693 2009
13
Helicobacter pylori cagA status and peptic ulcer disease in Iran. 54 61
18612816 2009
14
[Genetic features of Helicobacter pylori at patients with duodenal ulcer]. 54 61
20469711 2009
15
Helicobacter pylori and non-malignant diseases. 54 61
18783518 2008
16
Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib. 54 61
18711705 2008
17
vacA genotypes of Helicobacter pylori in relation to cagA status and clinical outcomes in Iranian populations. 54 61
18653971 2008
18
Zollinger-Ellison syndrome: a personal perspective. 54 61
18646472 2008
19
Differences in virulence markers between Helicobacter pylori strains from Iraq and those from Iran: potential importance of regional differences in H. pylori-associated disease. 54 61
18353934 2008
20
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. 54 61
18381949 2008
21
Peptic ulceration may be a hormonal deficiency disease. 54 61
18280672 2008
22
Future expectations in the prophylaxis of intestinal bleeding. 54 61
18346690 2008
23
Epidemiology of acute upper gastrointestinal bleeding. 54 61
18346679 2008
24
Prevalence of cagA in relation to clinical presentation of Helicobacter pylori infection in Egypt. 54 61
19086246 2008
25
Preferential induction of transforming growth factor-beta production in gastric epithelial cells and monocytes by Helicobacter pylori soluble proteins. 54 61
17922404 2007
26
Association between Helicobacter pylori genotypes and gastric disorders in relation to the cag pathogenicity island. 54 61
17521839 2007
27
Helicobacter pylori cagA and iceA genotypes status and risk of peptic ulcer in Saudi patients. 54 61
17334464 2007
28
Gastrinoma--morphological aspects. 54 61
17985091 2007
29
Helicobacter pylori cag pathogenicity island genes: clinical relevance for peptic ulcer disease development in Brazil. 54 61
17172510 2007
30
Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. 54 61
17088110 2006
31
Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features. 54 61
17006979 2006
32
Association of H pylori cagA and vacA genotypes and IL-8 gene polymorphisms with clinical outcome of infection in Iranian patients with gastrointestinal diseases. 54 61
16937534 2006
33
Significance of cagA status and vacA subtypes of Helicobacter pylori in determining gastric histopathology: virulence markers of H. pylori and histopathology. 54 61
16724992 2006
34
[Microbiologic, serologic diagnosis, and genotypification of Helicobacter pylori isolated from biopsies in children and adult people. Molecular detection of the cag pathogenicity island of Helicobacter pylori]. 54 61
17578080 2006
35
Lower prevalence of Helicobacter pylori infection with vacAs1a, cagA-positive, and babA2-positive genotype in erosive reflux esophagitis disease. 54 61
16302983 2005
36
Clinical and pathological importance of vacA allele heterogeneity and cagA status in peptic ulcer disease in patients from North Brazil. 54 61
16444419 2005
37
No correlation of babA2 with vacA and cagA genotypes of Helicobacter pylori and grading of gastritis from peptic ulcer disease patients in Brazil. 54 61
16302986 2005
38
Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection. 54 61
16268979 2005
39
[BabA2, oipA and cagE Helicobacter pylori genotypes in Colombian patients with gastroduodenal diseases]. 54 61
16276680 2005
40
Distinct diversity of vacA, cagA, and cagE genes of Helicobacter pylori associated with peptic ulcer in Japan. 54 61
16081930 2005
41
Clinical Relevance of the vacA, iceA, cagA, and flaA genes of Helicobacter pylori strains isolated in Eastern Taiwan. 54 61
15956417 2005
42
cagA gene variants in Malaysian Helicobacter pylori strains isolated from patients of different ethnic groups. 54 61
15866222 2005
43
cagA vacA alelles and babA2 genotypes of Helicobacter pylori associated with gastric disease in Brazilian adult patients. 54 61
15808313 2005
44
Distribution of Helicobacter pylori cagA, cagE and vacA in different ethnic groups in Kuala Lumpur, Malaysia. 54 61
15836708 2005
45
Gastrointestinal effects of selective and non-selective non-steroidal anti-inflammatory drugs. 54 61
15892675 2005
46
Zollinger-Ellison phenotype in the absence of hypergastrinemia and islet-cell tumor. 54 61
15879632 2005
47
Distribution of vacA alleles and cagA status of Helicobacter pylori in peptic ulcer disease and non-ulcer dyspepsia. 54 61
15606640 2004
48
Helicobacter pylori density and cagA status in cirrhotic patients: a case-control study. 54 61
15377296 2004
49
Genetic polymorphism of interleukin-8 (IL-8) is associated with Helicobacter pylori-induced duodenal ulcer. 54 61
15627645 2004
50
Diversity of vacA and cagA genes of Helicobacter pylori in Japanese children. 54 61
15298599 2004

Variations for Peptic Ulcer Disease

Expression for Peptic Ulcer Disease

Search GEO for disease gene expression data for Peptic Ulcer Disease.

Pathways for Peptic Ulcer Disease

Pathways related to Peptic Ulcer Disease according to GeneCards Suite gene sharing:

(show all 43)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.67 TP53 TNF PTGS2 PTGS1 IL1RN IL1B
2
Show member pathways
13.34 TP53 TNF PTGS2 IL1RN IL1B IL10
3
Show member pathways
13.1 TREM1 TP53 TNF IL1B IL10 HRAS
4
Show member pathways
12.93 TP53 TNF PTGS2 IL1B HRAS CXCL8
5
Show member pathways
12.57 TP53 TNF IL1B IL10 HRAS
6 12.5 TNF PTGS2 PTGS1 IL1RN IL1B IL10
7 12.36 TP53 TNF IL1B CXCL8
8
Show member pathways
12.3 TNF S100A8 PTGS2 IL1B CXCL8
9
Show member pathways
12.25 TNF PTGS2 IL1B IL10
10
Show member pathways
12.25 TP53 TNF IL1B IL10 CXCL8
11
Show member pathways
12.25 TP53 TNF PTGS2 IL1B HRAS CXCL8
12
Show member pathways
12.21 TP53 TNF PTGS2 PTGS1 IL1B CAT
13
Show member pathways
12.18 TNF PTGS2 IL1B IL10 HRAS
14 12.13 TNF IL1RN IL1B IL10 CXCL8
15
Show member pathways
12.04 TNF PTGS2 IL1RN IL1B HRAS CXCL8
16 12 TNF IL1B IL10 CXCL8
17 11.97 PTGS2 PTGS1 HRAS CYP2C19
18 11.93 TP53 TNF PTGS2 IL1B CXCL8
19 11.92 TP53 IL1B HRAS CXCL8
20 11.9 TNF PTGS2 IL1B CXCL8
21 11.89 TNF IL1B IL10 CXCL8
22 11.88 TNF IL1B HRAS CXCL8
23 11.77 TNF IL1B IL10
24
Show member pathways
11.74 TNF PTGS2 CXCL8
25 11.74 TNF IL1B IL10 CXCL8
26 11.73 TNF IL1B IL10
27 11.72 TP53 HRAS CXCL8
28 11.65 TNF IL1B CXCL8
29
Show member pathways
11.64 TNF PTGS2 IL1B CXCL8
30 11.6 TNF IL1B CXCL8
31 11.55 TP53 PTGS2 CXCL8
32 11.52 TNF PTGS2 HRAS
33 11.51 TNF PTGS2 IL1RN IL1B IL10
34 11.49 TNF IL1B IL10 CXCL8
35 11.49 TP53 TNF PTGS2 IL1B IL10 CXCL8
36 11.47 TP53 TNF HRAS
37 11.38 TNF IL1B IL10
38 11.35 TNF IL1B IL10
39 11.24 TNF IL1B IL10
40 10.79 TNF PTGS2 IL1RN IL1B IL10 CXCL8
41 10.74 TNF PTGS2 PTGS1 CXCL8
42 10.45 SCT GRP GAST
43 10.24 HRH2 GAST ATP4A

GO Terms for Peptic Ulcer Disease

Cellular components related to Peptic Ulcer Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 TREM1 TNF SCT S100A8 IL1RN IL1B
2 secretory granule lumen GO:0034774 9.46 S100A8 GRP GHRL CAT
3 extracellular space GO:0005615 9.4 TNF SCT S100A8 IL1RN IL1B IL10

Biological processes related to Peptic Ulcer Disease according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.28 IL1RN IL1B IL10 HRH2 HRAS GRP
2 immune response GO:0006955 10 TNF IL1RN IL1B IL10 HRH2 CXCL8
3 response to lipopolysaccharide GO:0032496 9.92 S100A8 PTGS2 IL1B IL10
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.89 TNF S100A8 IL1B CAT
5 response to oxidative stress GO:0006979 9.87 TP53 PTGS2 PTGS1 CAT
6 cellular oxidant detoxification GO:0098869 9.85 PTGS2 PTGS1 CAT
7 regulation of cell proliferation GO:0042127 9.85 TP53 TNF PTGS2 PTGS1 GHRL
8 positive regulation of interleukin-6 production GO:0032755 9.82 TNF IL1RN IL1B
9 positive regulation of JNK cascade GO:0046330 9.8 TNF IL1RN IL1B HRAS
10 negative regulation of cell proliferation GO:0008285 9.8 TP53 PTGS2 MEN1 IL1B IL10 HRAS
11 response to UV GO:0009411 9.79 TP53 MEN1 CAT
12 positive regulation of nitric oxide biosynthetic process GO:0045429 9.78 TNF PTGS2 IL1B
13 neutrophil chemotaxis GO:0030593 9.78 S100A8 IL1RN IL1B CXCL8
14 positive regulation of interferon-gamma production GO:0032729 9.77 TNF IL1B HRAS
15 cellular response to lipopolysaccharide GO:0071222 9.77 TNF IL1RN IL1B IL10 CXCL8
16 negative regulation of mitotic cell cycle GO:0045930 9.75 TP53 TNF IL10
17 decidualization GO:0046697 9.69 PTGS2 MEN1 GHRL
18 negative regulation of telomerase activity GO:0051974 9.67 TP53 MEN1
19 positive regulation of chemokine biosynthetic process GO:0045080 9.67 TNF IL1B
20 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.67 IL1RN IL10
21 cyclooxygenase pathway GO:0019371 9.66 PTGS2 PTGS1
22 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.66 IL10 GHRL
23 response to salt stress GO:0009651 9.65 TP53 TNF
24 endothelial cell apoptotic process GO:0072577 9.65 TNF IL10
25 positive regulation of lipid catabolic process GO:0050996 9.65 SCT IL1B
26 regulation of establishment of endothelial barrier GO:1903140 9.64 TNF IL1B
27 positive regulation of prostaglandin biosynthetic process GO:0031394 9.63 PTGS2 IL1B
28 negative regulation of cytokine secretion involved in immune response GO:0002740 9.63 TNF IL10
29 response to glucocorticoid GO:0051384 9.62 TNF PTGS2 IL1RN IL10
30 embryonic digestive tract development GO:0048566 9.61 TNF SCT CXCL8
31 sequestering of triglyceride GO:0030730 9.58 TNF IL1B
32 positive regulation of heterotypic cell-cell ad